PTG.WA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$13M	+9650.0%	$-2.70	$-2.70–$-2.70	—	1
2027	$119M	+815.4%	$10.90	$10.90–$10.90	—	1
2028	$134M	+12.6%	$9.00	$9.00–$9.00	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$3.10

Price

$22.90

Implied downside

-86%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
PTG.WAPoltreg S.A.	$21.90	-4.37%	$130M	—
AWM.WAAirway Medix S.A.	$0.28	-0.36%	$32M	—
CTX.WACaptor Therapeutics Spolka Akcyjna	$72.50	+0.28%	$459M	—
GMT.WAGenomtec S.A.	$3.61	+0.00%	$62M	—
ICE.WAMedinice S.A.	$57.40	-4.17%

Poltreg S.A.

Poltreg S.A. is a biotechnology enterprise based in Gdansk, Poland, specializing in the creation of therapeutic solutions for autoimmune conditions. The company's research and development efforts are centered on harnessing T-regulatory cells to develop treatments, specifically targeting type 1 diabetes in children and multiple sclerosis.

poltreg.bio

Employees: 37
IPO / List date: Nov 23, 2021
HQ: PL

Held by traders on TradeandTell

No one on the platform currently holds PTG.WA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in PTG.WA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded PTG.WA yet.